Form 4: Aadi Bioscience Executive Chairman Neil Desai Sells Shares

Neil Desai, Executive Chairman of Aadi Bioscience, sold shares of common stock on April 1st and 2nd, 2024, according to a Form 4 filing with the SEC.

Summary

• Neil Desai, the Executive Chairman of Aadi Bioscience, Inc., reported the sale of company stock in a Form 4 filing with the SEC.
• On April 1, 2024, Desai sold 17,772 shares of common stock at a weighted average price of $2.3127 per share.
• On April 2, 2024, Desai sold 22,228 shares of common stock at a weighted average price of $2.2275 per share.
• The sales were executed under a Rule 10b5-1 trading plan.
• Following these transactions, Desai directly owns no shares, but indirectly owns 1,371,543 shares through the Anishka Family Trust and 639,698 shares through the Anishka Irrevocable 2016 Trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports stock sales by an executive under a pre-existing trading plan. It doesn't inherently indicate positive or negative prospects for the company.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, potentially impacting the stock price.

Industry Context

Insider trading activity is closely monitored in the pharmaceutical industry, as it can provide insights into management's perspective on the company's prospects. Form 4 filings are a routine part of this monitoring process.

Comparison to Industry Standards

• Executive stock sales are common across the pharmaceutical industry.
• The use of Rule 10b5-1 trading plans is a standard practice to avoid accusations of insider trading.
• Comparing the size and frequency of these sales to those of executives at comparable companies like Mirati Therapeutics or Relay Therapeutics could provide further context.

Stakeholder Impact

• Shareholders may react to the news of executive stock sales, potentially influencing the stock price in the short term.

Key Dates